Insider · CIK 0001259780
Peter Kies
Files at INO (INOVIO PHARMACEUTICALS, INC.). First filing -, latest -.
In brief
Peter Kies files SEC Form 4 as CFO at INO (INOVIO PHARMACEUTICALS, INC.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Peter Kies has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 29 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 20, 2026 | INO INOVIO PHARMACEUTICALS, INC. | MOption exercise Common Stock | +8,700 | - | - | 47,542 | May 21, 2026 |
| May 20, 2026 | INO INOVIO PHARMACEUTICALS, INC. | FTax withholding Common Stock | -4,688 | $1.23 | $5,766 | 42,854 | May 21, 2026 |
| May 20, 2026 | INO INOVIO PHARMACEUTICALS, INC. | MOption exercise Restricted Stock Unitderivative | -8,700 | $0.00 | $0 | 17,400 | May 21, 2026 |
| May 20, 2026 | INO INOVIO PHARMACEUTICALS, INC. | AGrant or award Common Stock Optionderivative | +39,760 | $0.00 | $0 | 39,760 | May 21, 2026 |
| May 20, 2026 | INO INOVIO PHARMACEUTICALS, INC. | AGrant or award Restricted Stock Unitderivative | +32,480 | $0.00 | $0 | 32,480 | May 21, 2026 |
| May 15, 2026 | INO INOVIO PHARMACEUTICALS, INC. | MOption exercise Common Stock | +4,771 | - | - | 41,413 | May 18, 2026 |
| May 15, 2026 | INO INOVIO PHARMACEUTICALS, INC. | FTax withholding Common Stock | -2,571 | $1.30 | $3,342 | 38,842 | May 18, 2026 |
| May 15, 2026 | INO INOVIO PHARMACEUTICALS, INC. | MOption exercise Restricted Stock Unitderivative | -4,771 | $0.00 | $0 | 0 | May 18, 2026 |
| Mar 4, 2026 | INO INOVIO PHARMACEUTICALS, INC. | AGrant or award Common Stock Optionderivative | +31,240 | $0.00 | $0 | 31,240 | Mar 5, 2026 |
| Mar 4, 2026 | INO INOVIO PHARMACEUTICALS, INC. | AGrant or award Restricted Stock Unitderivative | +25,520 | $0.00 | $0 | 25,520 | Mar 5, 2026 |
| Feb 26, 2026 | INO INOVIO PHARMACEUTICALS, INC. | MOption exercise Common Stock | +5,010 | - | - | 35,267 | Feb 27, 2026 |
| Feb 26, 2026 | INO INOVIO PHARMACEUTICALS, INC. | FTax withholding Common Stock | -2,965 | $1.79 | $5,307 | 32,302 | Feb 27, 2026 |
| Feb 26, 2026 | INO INOVIO PHARMACEUTICALS, INC. | MOption exercise Common Stock | +10,634 | - | - | 42,936 | Feb 27, 2026 |
| Feb 26, 2026 | INO INOVIO PHARMACEUTICALS, INC. | FTax withholding Common Stock | -6,294 | $1.79 | $11k | 36,642 | Feb 27, 2026 |
| Feb 26, 2026 | INO INOVIO PHARMACEUTICALS, INC. | MOption exercise Restricted Stock Unitderivative | -5,010 | $0.00 | $0 | 5,009 | Feb 27, 2026 |
| Feb 26, 2026 | INO INOVIO PHARMACEUTICALS, INC. | MOption exercise Restricted Stock Unitderivative | -10,634 | $0.00 | $0 | 21,266 | Feb 27, 2026 |
| May 20, 2025 | INO INOVIO PHARMACEUTICALS, INC. | AGrant or award Restricted Stock Unitderivative | +26,100 | $0.00 | $0 | 26,100 | May 21, 2025 |
| May 20, 2025 | INO INOVIO PHARMACEUTICALS, INC. | AGrant or award Common Stock Optionderivative | +31,950 | $0.00 | $0 | 31,950 | May 21, 2025 |
| May 15, 2025 | INO INOVIO PHARMACEUTICALS, INC. | MOption exercise Common Stock | +4,771 | - | - | 32,823 | May 16, 2025 |
| May 15, 2025 | INO INOVIO PHARMACEUTICALS, INC. | FTax withholding Common Stock | -2,566 | $1.95 | $5,004 | 30,257 | May 16, 2025 |
| May 15, 2025 | INO INOVIO PHARMACEUTICALS, INC. | MOption exercise Restricted Stock Unitderivative | -4,771 | $0.00 | $0 | 4,771 | May 16, 2025 |
| Feb 26, 2025 | INO INOVIO PHARMACEUTICALS, INC. | MOption exercise Common Stock | +3,997 | - | - | 28,364 | Feb 28, 2025 |
| Feb 26, 2025 | INO INOVIO PHARMACEUTICALS, INC. | FTax withholding Common Stock | -2,362 | $1.98 | $4,677 | 26,002 | Feb 28, 2025 |
| Feb 26, 2025 | INO INOVIO PHARMACEUTICALS, INC. | MOption exercise Common Stock | +5,010 | - | - | 31,012 | Feb 28, 2025 |
| Feb 26, 2025 | INO INOVIO PHARMACEUTICALS, INC. | FTax withholding Common Stock | -2,960 | $1.98 | $5,861 | 28,052 | Feb 28, 2025 |
| Feb 26, 2025 | INO INOVIO PHARMACEUTICALS, INC. | MOption exercise Restricted Stock Unitderivative | -3,997 | $0.00 | $0 | 0 | Feb 28, 2025 |
| Feb 26, 2025 | INO INOVIO PHARMACEUTICALS, INC. | MOption exercise Restricted Stock Unitderivative | -5,010 | $0.00 | $0 | 10,019 | Feb 28, 2025 |
| Feb 27, 2025 | INO INOVIO PHARMACEUTICALS, INC. | AGrant or award Common Stock Optionderivative | +39,050 | $0.00 | $0 | 39,050 | Feb 28, 2025 |
| Feb 27, 2025 | INO INOVIO PHARMACEUTICALS, INC. | AGrant or award Restricted Stock Unitderivative | +31,900 | $0.00 | $0 | 31,900 | Feb 28, 2025 |
Questions about Peter Kies
Answered from the filings on this page, as of the latest one.
Is Peter Kies buying or selling?
Peter Kies has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Peter Kies's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Peter Kies has 0.
Where does Peter Kies file Form 4?
Peter Kies has filed Form 4 at INO (INOVIO PHARMACEUTICALS, INC.) as CFO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.